Skip to content

Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer

Comparing the Diagnostic Role of 18F-FDG PET/MRI and of 18F-FDG PET/CT Among Patients With Gastric Cancer:A Randomized Controlled Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03015298
Enrollment
100
Registered
2017-01-10
Start date
2017-01-31
Completion date
2018-06-30
Last updated
2017-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer Stage

Keywords

gastric cancer, Simultaneous PET/MRI, PET/CT

Brief summary

The results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.

Detailed description

A prospective comparison of PET/MRI and PET/CT for gastric cancer will be performed,to evaluate the value of PET/MRI in predicting the preoperative staging and resectability of gastric cancer and investigate the role of PET/MRI in gastric cancer diagnosis.The evaluation parameters are the diagnostic accuracy of gastric cancer staging( including the overall accuracy, sensitivity, and specificity) and the receiver operating characteristic (ROC).

Interventions

DEVICEPET/MRI

The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.

DEVICEPET/CT

At the next day of PET/MRI examination,A PET/CT examination will be performed.

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Histological diagnosis of gastric cancer 2. No previous treatment history for gastric cancer 3. Without complications of obstruction,bleeding and so on 4. Without severe diabetes,the levels of blood glucose \<6.2 mmol/L . 5. No cardiac pacemarker,never stimulator or other metal substitute materials in vivo.

Exclusion criteria

1. With other neoplastic disease. 2. Suffering acute inflammatory disease 3. History of chemo-radiotherapy 4. Suffering prostate hyperplasia,glaucoma

Design outcomes

Primary

MeasureTime frameDescription
The results of the PET/MRI and PET/CT examination3 daysTwo experienced radiologists independently assess the TNM staging of gastric cancer using preoperative PET/MRI and PET/CT images

Secondary

MeasureTime frameDescription
Results of CT/Endoscopic ultrasound(EUS) image3 daysExperienced radiologists assess definitely T stage in Tx, number of regional lymph node metastasis,with or without distant metastasis.
Numerical values of Standard uptake value(SUV)3 daysStandard uptake value(SUV) is defined as the ratio of the image derived radioactivity concentration and the whole body concentration of the injected radioactivity.
Apparent Diffusion Coefficient(ADC)3 daysApparent Diffusion Coefficient(ADC) will be measured using a curved Placement of region of interest(ROI) to include the high signal and be read out on ADC maps by Diffusion-weighted magnetic resonance imaging (DWI or DW-MRI) analysis software.
Histopathological diagnosis5 daysincluding definitely T stage in Tx, number of regional lymph node metastasis,result of histologic subtypes of carcinoma,result of other cytological examination.
The expression level of Receptors for vascular endothelial growth factor(VEGFR)5 daysAcquire from pathology results
Follow-up dataat lest 6 monthsresults of conventional imaging examination and tumor biomarkers examination.
The expression level of Receptor tyrosine-protein kinase erbB-2(HER2)5 daysAcquire from pathology results

Contacts

Primary ContactLin Chen, Master
chenlinbj@sina.com86-13801290395

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026